← All trials
NCT01616784
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2011
- Primary completion
- Jun 30, 2015
- Completion date
- Nov 30, 2015
- First posted
- Jun 12, 2012
- Last posted
- Jan 26, 2021
- Enrollment
- 267
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sheffield Hallam UniversityLead sponsor
- University of CambridgeCollaborator
- University of LondonCollaborator
- National Institute for Health Research, United KingdomCollaborator
- University of GlasgowCollaborator
- NHS LothianCollaborator
- University of NottinghamCollaborator
- Sheffield Hallam UniversityOverall official - principal investigator
- Sheffield Hallam UniversityOfficial
- Harrogate & District NHS Foundation TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.